Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...

Regeneron Pharmaceuticals Inc.'s victory against Amgen Inc. over anticompetitive drug bundling reinforces the necessity for ...

On May 15, 2025, a jury returned a verdict finding Amgen Inc. (“Amgen”) liable for antitrust violations and awarding Regeneron Pharmaceuticals, ...

A seminal decision concerning second medical use patents and questions over confidentiality were among the top talking points ...

Regeneron emphasized its proprietary technologies ... including the biggest companies in the world like Amgen. They went to clinical trials. They failed in every single Phase III trial.

From a valuation standpoint, Amgen is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 13.12 forward earnings, which is lower than 14.74 for the industry.

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

Incorporating chest CT imaging and respiratory symptoms into the chronic obstructive pulmonary disease (COPD) diagnostic ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

Patients with asthma who did not persist with biologic treatment had more exacerbations and used more oral corticosteroids, ...